Evaluating rilzabrutinib in the treatment of immune thrombocytopenia. [PDF]
ImmunotherapyKuter DJ, Ghanima W.
europepmc +1 more source
A genetically determined molecular switch modulates the anti-inflammatory potential of human IgA. [PDF]
Front ImmunolGibson AW +6 more
europepmc +1 more source
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B-Cell Malignancies. [PDF]
CPT Pharmacometrics Syst PharmacolDemin O +10 more
europepmc +1 more source
Vascular Endothelial Growth Factors and the Bmx Tyrosine Kinase in the Regulation of Angiogenesis and Lymphangiogenesis [PDF]
, 2003 Paavonen, Karri
core
Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First-in-human, randomized, ascending-dose studies. [PDF]
Br J Clin PharmacolKumagai Y +4 more
europepmc +1 more source
Cardiovascular toxicity of Bruton tyrosine kinase inhibitors: forget about selectivity but watch the clock. [PDF]
Blood AdvMinotti G.
europepmc +1 more source
Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification. [PDF]
OncotargetPatel JN, Singh J, Ghosh N.
europepmc +1 more source
Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments. [PDF]
World J GastroenterolBarone M.
europepmc +1 more source
Differential regulatory effects of the N-terminal region in SYK-fusion kinases reveal unique activation-inducible nuclear translocation of ITK-SYK. [PDF]
Sci RepHamasy A +8 more
europepmc +1 more source
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL. [PDF]
Hematology Am Soc Hematol Educ ProgramSilkenstedt E, Dreyling M.
europepmc +1 more source